Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: An analysis of international staging definitions

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 3070-3076

  Klimm, B ^a   Goergen, H ^a   Fuchs, M ^a   von Tresckow, B ^a   Boll B ^a   Meissner, J ^b   Glunz, A ^c   Diehl, V ^a   Eich, H T ^d   Engert, A ^a   Borchmann, P ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Chemotherapy; Combined modality treatment; Early stage hodgkin's lymphoma; Outcome; Risk factor

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DIAGNOSTIC TEST ACCURACY STUDY; EARLY CANCER; ERYTHROCYTE SEDIMENTATION RATE; FALSE POSITIVE RESULT; FEMALE; HODGKIN DISEASE; HUMAN; INTERNATIONAL COOPERATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MIDDLE AGED; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; TUMOR VOLUME;

CHEMOTHERAPY; COMBINED MODALITY TREATMENT; EARLY-STAGE HODGKIN'S LYMPHOMA; OUTCOME; RISK FACTOR;

ADOLESCENT; ADULT; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84888815021     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt413     Document Type: Article

References (16)

1. Engert A, Pluetschow A, Eich HT et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363: 640-652.
2. Eich HT, Diehl V, Görgen H et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28: 4199-4206.
3. Fermé C, Eghbali H, Meerwaldt JH et al. EORTC-GELA H8 trial: chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357: 1916-1927.
4. Meyer RM, Gospodarowicz MK, Connors JM et al. National Cancer Institute of Canada Clinical Trials Group; Eastern Cooperative Oncology Group: Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 4634-4642.
5. Hoppe RT, Advani RH, Ai WZ et al. Hodgkin lymphoma. J Natl Compr Canc Netw 2011; 9: 1020-1058.
6. Ballova V, Rüffer JU, Haverkamp H et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005; 16: 124-131.
7. Klimm B, Eich HT, Haverkamp H et al. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol 2007; 18: 357-363.
8. Hasenclever D, Diehl V. Prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506-1514.
9. Specht L, Nordentoft AM, Cold S et al. Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. relations to other prognostic factors and implications for choice of treatment. Cancer 1988; 61: 1719-1727.
10. Tubiana M, Henry-Amar M, van der Werf-Messing B et al. A multivariate analysis of prognostic factors in early stage Hodgkin's disease. Int J Radiat Oncol Biol Phys 1985; 11: 23-30.
11. Haybittle JL, Hayhoe FG, Easterling MJ et al. Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index. Lancet 1985; 1: 967-972.
12. Hasenclever D. The disappearance of prognostic factors in Hodgkin's disease. Ann Oncol 2002; 13(Suppl 1): 75-78.
13. Davison L, Albert-Green A, Tsang R et al. Outcome of patients with early stage Hodgkin lymphoma according to GHSG and NCIC-CTG risk classification: the Princess Margaret Hospital Experience. 17th Congress of the European Hematology Association 2012. Haematologica 2012; 97(s1): 1110a.
14. Advani RH, Hoppe RT, Maeda LS et al. Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience. Int J Radiat Oncol Biol Phys 2011; 81: 1374-1379.
15. von Tresckow B, Plütschow A, Fuchs M et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012; 30: 907-913.
16. Connors JM, Gascoyne RD, Hoskins P et al. Hodgkin lymphoma patients with stage IIB or stage II bulky disease have advanced disease and should not be included in limited stage trials. 2010 Annual Meeting of the American Society of Hematology. Blood 2010; 116: 417a.